A multicolor pattern scan laser should help laser therapy maintain or potentially expand its role in the treatment of certain retinal diseases even with the availability of effective new injectable pharmaceutical products, according to retinal specialists.
Modern Medicine Now
Loteprednol etabonate ophthalmic suspension 0.2% is a safe and effective first-line therapy for the treatment of seasonal and perennial allergic conjunctivitis.
Recent findings about uveal melanoma indicate that patients can be divided into high- and low-risk clasess, and that a mutation in one gene on chromosomes 3, BAP1, is closely associated with the high metastatic risk class 2 form of uveal melanoma.
The trabecular meshwork fails in glaucoma because of physical changes in the trabecular meshwork and altered signaling pathways.
When it comes to sunwear, frames get most of the attention.
The optimal use of mitomycin C in glaucoma surgery in pediatric patients is still controversial.
Analysis of data from two bilateral conjunctival allergen challenge studies of olopatadine hydrochloride ophthalmic solution 0.2% showed that ocular itching was prevented in a higher percentage of eyes treated with olopatadine when compared with vehicle.
Since the 2009 approval of bepotastine besilate ophthalmic solution 1.5% for ophthalmic use in the United States, further analysis of clinical trial data and new information from additional studies have revealed more about the drug's clinical utility.
Use of spectacles, contact lenses, or medications does not inhibit the progression of myopia for any length of time, as seen in in large major studies in children.
Therapy for ocular allergy has shown significant progress in recent years.